Key Takeaways:
Humana Inc. (NYSE: HUM) is set to report first-quarter earnings on April 29, with investors focused on whether its membership growth will fuel profits or an unsustainable rise in medical costs.
Given the questions posed by the bigger membership footprint, Humana is the “most debated stock in our coverage universe,” Mizuho Securities analyst Ann Hynes said in a recent note.
Wall Street expects adjusted earnings of $10.20 per share on revenue of $39.37 billion, according to FactSet data. The key figure is the medical cost ratio (MCR), which is projected to climb to 89.7 percent from 87 percent a year earlier.
Shares have rallied 34 percent since late March, but the report will test that recovery. The results will either validate the rebound or confirm fears sparked by a steep guidance cut for fiscal 2026, where Humana projected just $9 in EPS after earning $17.14 in 2025.
The market backdrop is challenging. Both UnitedHealth Group (NYSE: UNH) and Centene Corp. (NYSE: CNC) delivered first-quarter earnings that beat analyst estimates, driven by effective cost controls. UnitedHealth, which is up 12 percent year-to-date, saw its MCR improve to 84 percent and raised its full-year outlook. Centene’s stock jumped 14 percent after it posted an MCR of 87.3 percent, well below the 89.1 percent analysts feared, and also boosted its 2026 guidance.
This places pressure on Humana to demonstrate a similar handle on expenses. Unlike competitors who have been trimming their Medicare Advantage footprint, Humana’s membership has swelled, making it the “greatest risk” if healthcare utilization trends pick up, according to Mizuho.
Humana’s stock has been volatile, slumping after the government initially proposed a nearly flat payment rate for Medicare Advantage plans in 2027. However, shares rebounded after federal officials finalized a higher average payment increase of 2.48 percent for insurers.
Guggenheim analyst Jason Cassorla sees an upside, noting the company’s “ability to reprice its book annually and downsize relatively unattractive supplemental benefits over time.”
The upcoming earnings report is a critical test for Humana's strategy. A better-than-feared medical cost ratio could restore confidence in the Medicare Advantage business model, while a miss could see the stock’s recent gains evaporate. Investors will be listening closely to the April 29 call for any changes to the company's full-year guidance.
This article is for informational purposes only and does not constitute investment advice.
